mRNA-1345 Respiratory Syncytial Virus (RSV) Vaccine 2023
Moderna Inc.'s mRNA-1345 Respiratory Syncytial Virus (RSV) vaccine candidate encodes for a prefusion F glycoprotein, eliciting a superior neutralizing antibody response. The mRNA-1345 vaccine is a messenger RNA (mRNA) vaccine. This mRNA is entirely made in a laboratory and instructs your body to make small pieces of proteins. In addition, this vaccine candidate contains the mRNA code for the RSV glycoprotein F, which does not cause RSV infection but helps the body's immune system recognize and protect itself if it encounters the virus. Therefore, you cannot become infected with RSV by receiving the investigational vaccine.
The Company shared the first interim analysis of the Phase 1 study of mRNA-1345, through 1-month post-vaccination, of the younger adult cohorts on April 14, 2021. Results showed the vaccine candidate generated a geometric mean rise in neutralizing antibodies relative to a baseline of at least 11-fold. In addition, on February 22, 2022, Moderna confirmed the Data and Safety Monitoring Board for the RSV vaccine program had endorsed the start of the Phase 3 portion of the pivotal clinical study of mRNA-1345 in adults 60 years and older.
Moderna's pivotal Phase, 3 placebo-controlled clinical study of mRNA-1345, evaluates its effectiveness in older adults (60 yrs+). As of January 17, 2023, the pivotal Phase 3 RSV study of mRNA-1345 in older adults had accrued 36,604 cases required to complete our first interim efficacy analysis, demonstrating vaccine efficacy of 83.7% against RSV lower respiratory tract disease, defined by two or more symptoms in older adults. Based on these results, Moderna intends to submit mRNA-1345 for regulatory approval in 2023. The FDA had granted Fast Track designation for mRNA-1345 in adults older than 60.
As of January 2023, no U.S. Food and Drug Administration (FDA) approved RSV vaccines exist.
Massachusetts-based Moderna's mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology, and manufacturing and has allowed the development of therapeutics and vaccines. To learn more, visit www.modernatx.com.
The mRNA-1345 RSV vaccine candidate is indicated to prevent illness from RSV, a leading cause of respiratory illness in young children and older adults (65+). RSV is the most common cause of bronchiolitis (inflammation of the small airways in the lung) and pneumonia (infection of the lungs) in children younger than one year. According to the U.S. CDC, RSV leads each year, on average, to approximately 58,000 hospitalizations among children younger than five years old, 177,000 hospitalizations among adults 65 years and older, and 14,000 deaths among adults 65 years and older.
The interim data from a Phase 1 study in older adults ages 65-79 showed that a single mRNA-1345 vaccination of 50 µg, 100 µg, or 200 µg boosted neutralizing antibody titers against RSV-A by approximately 14-fold and against RSV-B by about 10-fold. Data were pooled across dose levels because there was no significant difference between doses.
mRNA-1345 News For 2021 - 2023
January 17, 2023 - Stéphane Bancel, Moderna's CEO, stated: "Respiratory diseases are a major public health priority given they have a significant health impact and are a leading cause of hospitalization. For these reasons, in addition to our mRNA-1345 RSV vaccine candidate, we are committed to developing a portfolio of respiratory mRNA vaccines to target the most significant viruses causing respiratory disease, including COVID-19, influenza, and human metapneumovirus."
March 24, 2022 - Moderna confirmed a Phase 1 RSV trial (mRNA-1345) is ongoing evaluating tolerability, reactogenicity, and immunogenicity in children, younger adults, older adults, and women of childbearing age. In an interim analysis, mRNA-1345 boosted RSV-neutralizing antibodies and was well-tolerated at all doses in younger and older adults.
March 9, 2022 - ConquerRSV, a pivotal Phase 3 trial in adults ≥ 60 years of age; expected enrollment is ~34,000 participants in multiple countries.
February 24, 2022 - Moderna, Inc. reported full-year 2021 revenues of $18.5 billion.
February 22, 2022 - Stéphane Bancel, CEO of Moderna, stated in a press release, "Our ultimate goal is to combine our RSV vaccine with our COVID-19 and flu boosters into a single-dose booster."
November 18, 2021 - Moderna, Inc. announced the first participant had been dosed in the ConquerRSV Phase 2/3 study of mRNA-1345, the Company's Respiratory Syncytial Virus (RSV) vaccine candidate.
November 4, 2021 - Moderna announced a pivotal Phase 2/3 study of respiratory syncytial virus (RSV) vaccine candidate (mRNA-1345) in older adults expected to begin in 2021; the study is expected to enroll approximately 34,000 participants, subject to agreement with regulatory authorities.
August 3, 2021 - Moderna, Inc. announced that the U.S. FDA had granted Fast Track designation for mRNA-1345, its investigational single-dose mRNA vaccine against RSV in adults older than 60.
May 6, 2021 - Moderna Inc., investor presentation regarding mRNA-1345 vaccine candidate.
April 14, 2021 - Moderna shared the first interim analysis of the Phase 1 study after 1-month post-vaccination of younger adults (18-49). 'mRNA-1345 was shown to increase RSV neutralizing antibodies in seropositive younger adults. As expected, neutralizing antibodies were confirmed to be present at baseline in all participants. In addition, a single vaccination of mRNA-1345 at the 50 or 100 μg dose level boosted neutralizing antibody titers against both serotypes of RSV-A and RSV-B with no apparent dose-response. At month 1, the geometric mean fold rise in neutralizing antibody relative to baseline was at least 20.5 for RSV-A and 11.7 for RSV-B.'
mRNA-1345 Clinical Trials
The pivotal ConquerRSV Phase 3 study of RSV in older adults (60+ years) is ongoing. This is a global study conducted in locations influenced by the epidemiology of RSV. The Company expects to enroll approximately 34,000 participants, who will be randomly assigned to receive a single injection of either mRNA-1345 vaccine at the selected dose or placebo in a 1:1 randomization ratio.
Clinical Trial NCT04528719: A Dose Escalation Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1345 in Healthy Adults and Children Who Are Respiratory Syncytial Virus Seropositive. Estimated Completion Date: September 30, 2023. The study will be conducted in 2 phases: Phase 2 and Phase 3. In the Phase 2 segment, 400 and 2,000 participants will be randomly assigned to receive a single injection of either the mRNA-1345 vaccine at the selected dose or a placebo in a 1:1 randomization ratio.